World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0003254533
Reproduction Date:

Title: Methylergometrine  
Author: World Heritage Encyclopedia
Language: English
Subject: Methysergide, 25CN-NBOMe, 25N-NBOMe, LPD-824, LSM-775
Collection: Lysergamides
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Trade names Methergine
  • Contraindicated
Legal status
  • (Prescription only)
Routes of
Pharmacokinetic data
Metabolism Liver
Biological half-life 30–120 min
Excretion Mostly bile
CAS Registry Number  Y
ATC code G02
PubChem CID:
ChemSpider  N
Synonyms Methylergobasine
Chemical data
Formula C20H25N3O2
Molecular mass 339.432 g/mol
Physical data
Melting point 172 °C (342 °F)
Solubility in water insoluble mg/mL (20 °C)

Methylergometrine (other names include methylergonovine, methylergobasin, methergine, and D-lysergic acid 1-butanolamide) is a synthetic analogue of ergonovine, a psychedelic alkaloid found in ergot, and many species of morning glory. It is a member of the ergoline family and chemically similar to LSD, ergine, ergometrine, and lysergic acid. Due to its oxytocic properties, it has a medical use in obstetrics. According to Jonathan Ott, methylergonovine has LSD-like actions above 2 milligrams. Clinical dosages are ten times lower.

Methylergometrine maleate is marketed under the trade name Methergine.


  • Uses 1
    • Obstetric use 1.1
    • Migraine 1.2
  • Contraindications 2
  • Side effects 3
  • Interactions 4
  • Mechanism of action 5
  • See Also 6
  • References 7


Obstetric use

Methylergometrine is a smooth muscle constrictor that mostly acts on the uterus. It is most commonly used to prevent or control excessive bleeding following childbirth and spontaneous or elective abortion, and also to aid in expulsion of retained products of conception after a missed abortion (miscarriage in which all or part of the fetus remains in the uterus) and to help deliver the placenta after childbirth. It is available as tablets or injection (IM or IV) or in liquid form to be taken orally.[1][2][3]


Methylergometrine is sometimes used for both prevention[4] and acute treatment[5] of migraine. It is an active metabolite of methysergide.


Methylergometrine is contraindicated in patients with hypertension and preeclampsia.[1] It is also contraindicated in HIV positive patients taking Protease inhibitors, Delavirdine and Efavirenz.[6]

Side effects

Adverse effects include:[1]

  • Cholinergic effects such as nausea, vomiting, and diarrhea
  • Dizziness
  • Pulmonary hypertension
  • Coronary artery vasoconstriction
  • Severe systemic hypertension (especially in patients with preeclampsia)
  • Convulsions

In excessive doses, methylergometrine can also lead to cramping, respiratory depression and coma.[1]


Methylergometrine likely interacts with drugs that inhibit the liver enzyme CYP3A4, such as azole antifungals, macrolide antibiotics and many HIV drugs. It can also increase constriction of blood vessels caused by sympathomimetic drugs and other ergot alkaloids.[1]

Mechanism of action

Methylergometrine is a partial agonist/antagonist on serotonergic, dopaminergic and alpha-adrenergic receptors. Its specific binding and activation pattern on these receptors leads to a highly, if not completely, specific contraction of smooth uterus muscle via 5-HT2A serotonin receptors,[7] while blood vessels are affected to a lesser extent compared to other ergot alkaloids.[1]

See Also



  1. ^ a b c d e f Jasek, W, ed. (2007). Austria-Codex (in German) (62nd ed.). Vienna: Österreichischer Apothekerverlag. pp. 5193–5.  
  2. ^ Mutschler, Ernst; Schäfer-Korting, Monika (2001). Arzneimittelwirkungen (in German) (8 ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. p. 447.  
  3. ^ Fachinformation des Arzneimittel-Kompendium der Schweiz: Methergin (German)
  4. ^ Koehler, PJ; Tfelt-Hansen PC (Nov 2008). "History of methysergide in migraine.". Cephalalgia 28 (11): 1126–35.  
  5. ^ Niño-Maldonado, Alfredo; Gary Caballero-García; Wilfrido Mercado-Bochero; Fernando Rico-Villademoros; Elena P Calandre (8 Nov 2009). "Efficacy and tolerability of intravenous methylergonovine in migraine female patients attending the emergency department: a pilot open-label study". Head Face Med 5 (21).  
  6. ^
  7. ^ Heinz Pertz, Eckart Eich (1999). "Ergot alkaloids and their derivatives as ligands for serotoninergic, dopaminergic and adrenergic receptors". In Vladimír Křen,Ladislav Cvak. Ergot: the genus Claviceps. CRC Press. pp. 411–440.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.